XML 117 R49.htm IDEA: XBRL DOCUMENT v2.4.0.8
Business combinations (Details 1) (USD $)
In Millions, unless otherwise specified
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Sep. 30, 2013
Onyx Pharmaceuticals, Inc. [Member]
Sep. 30, 2013
Onyx Pharmaceuticals, Inc. [Member]
Developed Product Technology Rights [Member]
Sep. 30, 2013
Onyx Pharmaceuticals, Inc. [Member]
Licensing Rights [Member]
Allocation of the total consideration to the acquisition date fair values of assets acquired and liabilities assumed            
Cash and cash equivalents       $ 319    
Marketable securities       337    
Inventories       250    
Indefinite-lived intangible assets - IPR&D       1,160    
Finite-lived intangible assets         5,910 2,792
Goodwill 14,968 12,662 11,750 2,526    
Convertible debt       (742)    
Assumed contingent consideration       (261)    
Deferred tax assets (liabilities), net       (2,918)    
Other assets (liabilities), net       142    
Total consideration       $ 9,515